Viking Therapeutics VKTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$158.33M-247% | -$157.66M-345% | -$90.79M-264% | -$65.56M-195% | -$45.63M-66.8% | ||
| $10.34M-8.9% | $8.59M+51.5% | $7.34M-18.3% | $13.55M+91.3% | $11.35M+42.2% | ||
| -$113.98M-118% | -$85.29M-174% | -$94M-328% | -$47.06M-65.1% | -$52.33M-753% | ||
| $54.19M-14.3% | $75.61M— | $160.03M— | $42.51M+134% | $63.25M+114% | ||
| $12.08M+3,360% | $75.1M+7,410% | $480K-81.0% | $507K-82.5% | $349K-99.9% | ||
| -$47.71M-524% | $65.43M+377% | $66.5M— | $0+100% | $11.26M-92.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's cash flow data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.